Status:
COMPLETED
Neuromodulation in COVID-19 Patients
Lead Sponsor:
D'Or Institute for Research and Education
Collaborating Sponsors:
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Conditions:
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
This clinical study is aimed at investigating the effects of transcranial direct current stimulation (tDCS) on COVID-19 patients not admitted to the intensive care unit. The tDCS is a non-invasive bra...
Eligibility Criteria
Inclusion
- suspected or confirmed diagnosis for SARS-CoV-2;
- ability to understand and execute the proposed protocol;
- vital signs (body temperature \<38ºC, blood pressure between 90 x 60mmHg and 140 x 90 mmHg, respiratory rate between 12 e 30 bpm).
Exclusion
- dyspnea or signs of respiratory effort;
- SpO2 ≤ 90%;
- hemodynamic instability;
- deep vein thrombosis, active bleeding, use of cardiac pacemaker;
- injury, pain or metallic implants in the cranium or scalp;
- seizure history;
- suspected or confirmed pregnancy;
- concomitant or previous rheumatic or neurological diseases;
- severe psychiatric diseases (schizophrenia, bipolar disorder, intellectual disability);
- severe musculoskeletal and/or integumentary disorders;
- severe psychiatric disorders;
- severe liver or kidney disease.
Key Trial Info
Start Date :
August 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04808284
Start Date
August 10 2021
End Date
October 11 2021
Last Update
October 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
D'Or Institute for Research and Education (IDOR)
Rio de Janeiro, Rio de Janeiro, Brazil, 22.281-100